Literature DB >> 15667573

Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects.

Catherine S Davies1, Claire L Harris, B Paul Morgan.   

Abstract

Type 1 diabetes is associated with anaemia. Although the underlying mechanisms remain unclear, the accompanying reticulocytosis implies that erythrocyte lifespan in the circulation is shortened. Among the factors that permit prolonged survival of erythrocytes are the membrane complement regulators. In conditions such as paroxysmal nocturnal haemoglobinuria, where erythrocyte expression of these regulators is reduced, erythrocyte survival is compromised and anaemia follows. Recent in vitro evidence indicates that one of the key membrane complement regulators, CD59, is inactivated by glycation in the presence of high concentrations of glucose or other glycating sugars. To ascertain whether glycation-induced inactivation of CD59 occurrs in vivo we examined CD59 surface expression and function on erythrocytes from a cohort with poorly controlled type 1 diabetes (hyperglycaemic) and from matched normoglycaemic controls. Although expression of CD59, assessed using polyclonal anti-CD59 antiserum, was similar in the two groups, erythrocytes from hyperglycaemic individuals were more susceptible to lysis by complement, entirely as a result of the loss of functional CD59. These data implicate glycation-induced inactivation of CD59 as a factor contributing to anaemia in type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667573      PMCID: PMC1782070          DOI: 10.1111/j.1365-2567.2004.02086.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria.

Authors:  M Yamashina; E Ueda; T Kinoshita; T Takami; A Ojima; H Ono; H Tanaka; N Kondo; T Orii; N Okada
Journal:  N Engl J Med       Date:  1990-10-25       Impact factor: 91.245

2.  Impairment by glycation of immunoglobulin G Fc fragment function.

Authors:  R Dolhofer-Bliesener; K D Gerbitz
Journal:  Scand J Clin Lab Invest       Date:  1990-11       Impact factor: 1.713

3.  Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59.

Authors:  C L Harris; K S Kan; G T Stevenson; B P Morgan
Journal:  Clin Exp Immunol       Date:  1997-02       Impact factor: 4.330

4.  Haematocrit, glycosylated haemoglobin and diabetic microangiopathy.

Authors:  R Kawahara
Journal:  Diabetologia       Date:  1980-11       Impact factor: 10.122

5.  Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.

Authors:  D L Bodian; S J Davis; B P Morgan; N K Rushmere
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

6.  The principal site of glycation of human complement factor B.

Authors:  M A Niemann; A S Bhown; E J Miller
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

7.  Nonenzymatic glycosylation of immunoglobulin G impairs complement fixation.

Authors:  P J Hennessey; C T Black; R J Andrassy
Journal:  JPEN J Parenter Enteral Nutr       Date:  1991 Jan-Feb       Impact factor: 4.016

8.  Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.

Authors:  S Meri; B P Morgan; A Davies; R H Daniels; M G Olavesen; H Waldmann; P J Lachmann
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

9.  Mapping the active site of CD59.

Authors:  J Yu; R Abagyan; S Dong; A Gilbert; V Nussenzweig; S Tomlinson
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

Review 10.  Glycation products and the pathogenesis of diabetic complications.

Authors:  M Brownlee
Journal:  Diabetes Care       Date:  1992-12       Impact factor: 19.112

View more
  10 in total

1.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

2.  Complement regulation in tenocytes under the influence of leukocytes in an indirect co-culture model.

Authors:  Sandeep Silawal; Benjamin Kohl; Georg Girke; Tobias Schneider; Gundula Schulze-Tanzil
Journal:  Inflamm Res       Date:  2021-03-27       Impact factor: 4.575

3.  A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Sonia Cantel; Amol Kavishwar; Allison Goldfine; Neil Herring; Lynn Bry; Michael Chorev; Jose A Halperin
Journal:  Am J Hematol       Date:  2013-06-20       Impact factor: 10.047

Review 4.  Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

Authors:  Robert A DeAngelis; Edimara S Reis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

5.  Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans.

Authors:  Pamela Ghosh; Anand Vaidya; Rupam Sahoo; Allison Goldfine; Neil Herring; Lynn Bry; Michael Chorev; Jose A Halperin
Journal:  J Clin Endocrinol Metab       Date:  2014-03-14       Impact factor: 5.958

Review 6.  The eye as a complement dysregulation hotspot.

Authors:  Simon J Clark; Paul N Bishop
Journal:  Semin Immunopathol       Date:  2017-09-25       Impact factor: 9.623

7.  Plasma glycated CD59 (gCD59), a novel biomarker for the diagnosis, management and follow up of women with Gestational Diabetes (GDM) - protocol for prospective cohort study.

Authors:  D Bogdanet; P M O'Shea; J Halperin; F Dunne
Journal:  BMC Pregnancy Childbirth       Date:  2020-07-18       Impact factor: 3.007

8.  Associations of dicarbonyl stress with complement activation: the CODAM study.

Authors:  Ying Xin; Elisabeth Hertle; Carla J H van der Kallen; Casper G Schalkwijk; Coen D A Stehouwer; Marleen M J van Greevenbroek
Journal:  Diabetologia       Date:  2020-01-28       Impact factor: 10.122

9.  Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma.

Authors:  Rossen M Donev; Lisa C Gray; Baalasubramanian Sivasankar; Timothy R Hughes; Carmen W van den Berg; B Paul Morgan
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

Review 10.  Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy.

Authors:  Timothy S Kern
Journal:  Exp Diabetes Res       Date:  2007
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.